Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis

Critical Care Medicine

Volumn 38, Issue 9, 2010, Pages 1802-1808

  Kalil, Andre C ^a   Murthy, Madhu H ^b   Hermsen, Elizabeth D ^a,c   Neto, Felipe K ^d   Sun, Junfeng ^e   Rupp, Mark E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b West Valley Hospital   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

^d PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

linezolid; pneumonia; teicoplanin; vancomycin

Indexed keywords

LINEZOLID; TEICOPLANIN; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; ERADICATION THERAPY; HOSPITAL INFECTION; HUMAN; INFECTION RISK; KIDNEY FAILURE; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING; CHEMICALLY INDUCED; CROSS INFECTION; MEDICAL EDUCATION; MICROBIOLOGY; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACETAMIDES; ANTI-BACTERIAL AGENTS; CROSS INFECTION; EDUCATION, MEDICAL, CONTINUING; HUMANS; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; TEICOPLANIN; THROMBOCYTOPENIA; VANCOMYCIN;

EID: 77956232182     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181eb3b96     Document Type: Article

References (28)

1. American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
2. Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
3. Conte JE Jr, Golden JA, Kipps J, et al: Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46: 1475-1480.
4. Boselli E, Breilh D, Rimmele T, et al: Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005; 33:1529-1533.
5. Honeybourne D, Tobin C, Jevons G, et al: Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003; 51: 1431-1434.
6. Georges H, Leroy O, Alfandari S, et al: Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 1997; 16:385-388.
7. Lamer C, de Beco V, Soler P, et al: Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281-286.
8. Scheetz MH, Wunderink RG, Postelnick MJ, et al: Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant staphylococcus aureus pneumonia. Pharmacotherapy 2006; 26:539-550.
9. Luna CM, Bruno DA, Garcia-Morato J, et al: Effect of linezolid compared with glycopeptides in methicillin-resistant staphylococcus aureus severe pneumonia in piglets. Chest 2009; 135:1564-1571.
10. Kiem S, Schentag JJ: Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008; 52:24-36.
11. Wunderink RG, Rello J, Cammarata SK, et al: Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-1797.
12. Powers JH, Ross DB, Lin D, et al: Linezolid and vancomycin for methicillin-resistant staphylococcus aureus nosocomial pneumonia: The subtleties of subgroup analyses. Chest 2004; 126:314-316.
13. Kalil AC, Puumala SE, Stoner J: Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia. Chest 2004; 125:2370-2371.
14. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560.
15. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
16. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
17. Moher D, Cook DJ, Eastwood S, et al: Improving the quality of reports of metaanalyses of randomised controlled trials: The QUOROM statement. quality of reporting of meta-analyses. Lancet 1999; 354: 1896-1900.
18. Sterne JA, Gavaghan D, Egger M: Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53:1119-1129.
19. Cepeda JA, Whitehouse T, Cooper B, et al: Linezolid versus teicoplanin in the treatment of gram-positive infections in the critically ill: A randomized, double-blind, multicentre study. J Antimicrob Chemother 2004; 53: 345-355.
20. Wilcox M, Nathwani D, Dryden M: Linezolid compared with teicoplanin for the treatment of suspected or proven gram-positive infections. J Antimicrob Chemother 2004; 53: 335-344.
21. Rubinstein E, Cammarata S, Oliphant T, et al: Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-412.
22. Stevens DL, Herr D, Lampiris H, et al: Linezolid versus vancomycin for the treatment of methicillin-resistant staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481-1490.
23. Kaplan SL, Deville JG, Yogev R, et al: Linezolid versus vancomycin for treatment of resistant gram-positive infections in children. Pediatr Infect Dis J 2003; 22:677-686.
24. Wunderink RG, Cammarata SK, Oliphant TH, et al: Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25:980-992.
25. Jaksic B, Martinelli G, Perez-Oteyza J, et al: Efficacy and safety of linezolid compared with vancomycin in a randomized, doubleblind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006; 42: 597-607.
26. Kohno S, Yamaguchi K, Aikawa N, et al: Linezolid versus vancomycin for the treatment of infections caused by methicillinresistant staphylococcus aureus in japan. J Antimicrob Chemother 2007; 60: 1361-1369.
27. Wunderink RG, Mendelson MH, Somero MS, et al: Early microbiologic response to linezolid versus vancomycin in ventilatorassociated pneumonia (VAP) due to methicillin-resistant staphylococcus aureus (MRSA). Chest 2008; 1200-1207.
28. Falagas ME, Siempos II, Vardakas KZ: Linezolid versus glycopeptide or beta-lactam for treatment of gram-positive bacterial infections: Meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8:53-66